Sign in
GNFT Stock Price, Chart, Stats & News
Genfit S.A.
Save
445.68M
Market cap
–
Current P/E
7.27x
Forward P/E
GNFT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 101.36% |
Operating margin | -67.25% |
Pretax margin | -93.17% |
Net margin | -93.54% |
Effective tax rate | 4.85% |
ROA | -17.89% |
ROE | -63.70% |
D/E | 2.65x |
Interest coverage ratio | -11.63x |
GNFT valuation
P/E | – |
P/S | 9.32x |
P/B | 7.36x |
P/CF | -121.54x |
P/FCF | -86.36x |
P/OCF | -121.54x |
PEG | 0.00x |
EV multiple | -15.26x |
About
Genfit S. A. operates as a biopharmaceutical company dedicated to discovering and advancing novel therapeutic candidates and diagnostic solutions for a range of metabolic and liver-related diseases. Its most advanced drug candidate, Elafibranor, is currently undergoing Phase 3 clinical evaluation for the treatment of primary biliary cholangitis (PBC).
Similar securities
Based on sector and market capitalization
Report issue